This ultimately culminates in an inability of the β-cells to produce sufficient insulin to overcome the lowered sensitivity, thus resulting in fasting hyperglycemia, which is clinically categorized as T2D [4]. This evidence concerns the gene INS and type 2 diabetes mellitus.